Key facts
| Recalling firm | Sunny Pharmtech Inc. |
|---|---|
| Manufacturer | Not disclosed in the FDA record. |
| Brand name | Not disclosed in the FDA record. |
| Product description | Cyclophosphamide for Injection, USP, 2 gram/vial, One Single-Dose Vial, Rx only, Manufactured for: Long Grove Pharmaceuticals, LLC, Rosemont, IL 60018. Manufactured in Taiwan, NDC 81298-8114-1 |
| Classification | Class I |
| Recall number | D-0744-2026 |
| Report date | Not disclosed in the FDA record. |
| Status | Ongoing |
| Reason for recall | Presence of Particulate Matter; identified as stainless steel |
What this classification means
A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class I, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.
What consumers should do
Facilities, clinicians, and consumers holding an affected unit or lot of Cyclophosphamide for Injection, USP, 2 gram/vial, One Single-Dose Vial, Rx only, Manufactured for: Long Grove Pharmaceuticals, LLC, Rosemont, IL 60018. Manufactured in Taiwan, NDC 81298-8114-1 should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Sunny Pharmtech Inc.. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Sunny Pharmtech Inc. should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Sunny Pharmtech Inc. directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.
Sunny Pharmtech Inc.’s FDA history
Argus HQ has recorded 2 total FDA actions tied to Sunny Pharmtech Inc.: 0 warning letters, 2 recalls, 0 approval records, and 0 Form 483 inspection citations.
Frequently asked questions
- What is the recall class for Sunny Pharmtech Inc.'s recall?
- FDA classified this recall as Class I. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death.
- Why was Cyclophosphamide for Injection, USP, 2 gram/vial, One Single recalled?
- FDA's recall record states the reason as: Presence of Particulate Matter; identified as stainless steel
- Who should I contact about this recall?
- Contact Sunny Pharmtech Inc. directly, or the distributor/pharmacy that supplied the product, to confirm whether your specific lot or unit is affected. Argus HQ aggregates the public FDA recall record and is not the recalling firm.
- Has Sunny Pharmtech Inc. had other FDA recalls or enforcement actions?
- Yes. Argus HQ has recorded 2 total FDA actions tied to Sunny Pharmtech Inc., including 2 recalls and 0 warning letters.
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for Sunny Pharmtech Inc.Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Class I Recall: Cyclophosphamide for Injection, USP, 2 gram/vial, One Single-Dose… by Sunny Pharmtech Inc. — Recall Details. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/recall/sunny-pharmtech-d-0744-2026-2026-08-12
"FDA Class I Recall: Cyclophosphamide for Injection, USP, 2 gram/vial, One Single-Dose… by Sunny Pharmtech Inc. — Recall Details." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/recall/sunny-pharmtech-d-0744-2026-2026-08-12.
Argus HQ Research. "FDA Class I Recall: Cyclophosphamide for Injection, USP, 2 gram/vial, One Single-Dose… by Sunny Pharmtech Inc. — Recall Details." Digital Empire Holdings LLC. Accessed September 3, 2026. https://argushq.ai/recall/sunny-pharmtech-d-0744-2026-2026-08-12.
@misc{argushq_argushq_ai_recall_sunny_pharmtech_d_0744_2026_2026_08_12_2026,
title = {FDA Class I Recall: Cyclophosphamide for Injection, USP, 2 gram/vial, One Single-Dose… by Sunny Pharmtech Inc. — Recall Details},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/recall/sunny-pharmtech-d-0744-2026-2026-08-12},
note = {Accessed: September 3, 2026}
}Source: FDA.gov — Recalls ↗

